Home ›
Nasopharyngeal Head and Neck Cancer Trials ›
NCT06194656
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
This phase II study will be conducted in two parts (Ⅱa and Ⅱb), with a 21-day treatment cycle until disease progression, intolerable toxicity, withdrawal of informed consent, death, initiation of new anti-tumor treatment or loss of follow-up.
Trial Details
NCT ID NCT06194656
Phase PHASE2
Sponsor Shanghai Institute Of Biological Products
Status RECRUITING
Cancer Type Nasopharyngeal Head and Neck Cancer
Interventions HER3 Monoclonal antibodies-Dose A HER3 Monoclonal antibodies-Dose B HER3 Monoclonal antibodies-Dose C HER3 Monoclonal antibodies-Dose D Placebo Cetuximab injection
Locations (sample) Shanghai, Shanghai Municipality, China|31.22222,121.45806 Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
The subjects voluntarily participated in the study and signed the informed consent. Male and female aged between 18 and 75 years old, regardless of gender. Patients with recurrent/metastatic advanced HNSCC who have been diagnosed by histology or cytology, progressed or intolerant after previous immunot… During the screening period, subjects must provide tumor tissues and blood samples for biomarker detection. If the subject does not have an archive…
For full eligibility, visit ClinicalTrials.gov .